Battery Ventures Backs ExactTarget, $22M for Tokai Pharmaceuticals, Ironwood Banks $40M in European Deal, & Much Much More Boston-Area Deals News

Xconomy Boston — 

Sheesh there were a lot of deals last week! Let’s get to it.

Ironwood Pharmaceuticals of Cambridge, MA, earned $40 million in upfront payments as part of a deal giving Barcelona, Spain-based Laboratorios Almirall European development and commercial rights to linaclotide, Ironwood’s experimental drug for irritable bowel syndrome with constipation. The Spanish firm will potentially pay Ironwood another $15 million for reaching near-term milestones, plus $40 million before linaclotide is commercialized.

—Burlington, VT-based Vermedx raised $500,000 in a Series A financing to help develop information technology tools for the diabetes care market. Shelburne, VT-based FreshTracks Capital led the deal.

—Waltham, MA-based diagnostics maker Inverness Medical Innovations (NYSE:IMA) announced a $200 million public offering of senior subordinated notes due in 2016.

—Providence, RI-based NABsys, a startup developing fast, cheap DNA sequencing technology for use in healthcare, raised $4 million in a Series A financing round led by Point Judith Capital and joined by the likes of the Slater Technology Fund.

—Medical devices firm Arsenal Medical of Watertown, MA, reportedly raised $8.2 million in a third round of venture financing. The company, which was formerly called WMR Biomedical, is developing devices incorporating advanced biomaterials for the cardiovascular and ophthalmology markets.

—Acton, MA-based Azuki Systems (formerly called PeerMeta—I guess local startups are in the mood for change) raised $6 million in equity financing from previous backers Kepha Partners and Sigma Partners, as well as company executives. Azuki provides a cloud-based platform for mobile websites, mobile applications, and desktop widgets.

Synageva BioPharma of Waltham, MA, collected $3 million more of a previously announced private equity round, bringing the total … Next Page »

Single PageCurrently on Page: 1 2

By posting a comment, you agree to our terms and conditions.

Comments are closed.